Duru O Kenrik, Turk Norman, Ettner Susan L, Neugebauer Romain, Moin Tannaz, Li Jinnan, Kimbro Lindsay, Chan Charles, Luchs Robert H, Keckhafer Abigail M, Kirvan Anya, Ho Sam, Mangione Carol M
David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.
Fielding School of Public Health, University of California, Los Angeles, CA, USA.
J Gen Intern Med. 2015 Nov;30(11):1645-50. doi: 10.1007/s11606-015-3284-8. Epub 2015 May 6.
Reducing patient cost-sharing and engaging patients in disease management activities have been shown to increase uptake of evidence-based care.
To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the Diabetes Health Plan/DHP) on medication adherence among eligible employees and dependents.
Employer-level "intent to treat" cohort study, including data from eligible employees and their dependents with diabetes, regardless of whether they were enrolled in the DHP.
Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011.
Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences.
The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHP participants are notified up front that they must engage in their own health care (e.g., receiving diabetes-related screening) in order to remain enrolled.
Mean employee adherence to metformin, statins, and ACE/ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC).
Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69 %. In the first year after DHP implementation, predicted employer-level adherence for metformin (+4.9 percentage points, p = 0.017), statins (+4.8, p = 0.019), and ACE/ARBs (+4.4, p = 0.02) was higher with DHP purchase.
Non-randomized, observational study.
The Diabetes Health Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12 months.
降低患者自付费用并让患者参与疾病管理活动已被证明能提高循证医疗的利用率。
评估雇主购买一项具有降低自付费用和疾病管理功能的特定疾病计划(糖尿病健康计划/DHP)对符合条件的员工及其家属药物依从性的影响。
雇主层面的“意向性治疗”队列研究,包括来自符合条件的患有糖尿病的员工及其家属的数据,无论他们是否参加了DHP。
在2009年、2010年和/或2011年与一家大型全国性健康计划管理机构签约的雇主。
购买了DHP的10家雇主和未购买的191家雇主(对照组)。采用逆概率加权(IPW)估计来调整组间差异。
DHP包括免费或低成本的药物和医生诊疗。参保策略和具体福利设计由雇主决定,实际情况各不相同。DHP参与者会预先被告知,他们必须参与自身的医疗保健(如接受糖尿病相关筛查)才能继续参保。
在DHP实施一年后,以覆盖天数比例(PDC)衡量的雇主层面员工对二甲双胍、他汀类药物和ACE/ARBs的平均依从性。
DHP雇主和对照雇主对这三种药物的基线依从性相似,范围在64%至69%之间。在DHP实施后的第一年,购买DHP的雇主层面,二甲双胍的预测依从性提高了4.9个百分点(p = 0.017),他汀类药物提高了4.8个百分点(p = 0.019),ACE/ARBs提高了4.4个百分点(p = 0.02)。
非随机观察性研究。
糖尿病健康计划是一项创新的健康计划,它将降低自付费用和疾病管理与参保者预先参与自身医疗保健的要求相结合,与12个月时药物依从性的适度改善相关。